Publications

5674 Results

Outcome of African Americans on Southwest Oncolgy Group (SWOG) breast cancer adjuvant therapy trials

Authors
KS Albain;JM Unger;LF Hutchins;SE Rivkin;S Martino;RB Livingston;CK Osborne
Journal / Conference
Breast Cancer Research and Treatment 82(Suppl.1):S12(#21)
Year
2003
Research Committee(s)
Breast

Prognostic factors and response to fludarabine therapy in Waldenstrom's Macroglobulinemia: an update of a US Intergroup trial (SWOG S9003)

Authors
MV Dhodapkar;JL Jacobson;MA Gertz;JJ Crowley;B Barlogie
Journal / Conference
Seminars in Oncology 30(2):220-225
Year
2003
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9003

The influence of finasteride on the development of prostate cancer

Authors
IM Thompson;PJ Goodman;CM Tangen;MS Lucia;GJ Miller;LG Ford;MM Lieber;RD Cespedes;JN Atkins;SM Lippman;SM Carlin;A Ryan;CM Szczepanek;JJ Crowley;CA Coltman Jr
Journal / Conference
New England Journal of Medicine 349:215-224
Year
2003
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

CHOP followed by tositumomab/iodine I 131 tositumomab (Bexxar) for treatment of newly diagnosed follicular non-Hodgkin's Lymphomas: a phase II trial of the Southwest Oncology Group (S9911)

Authors
OW Press;JM Unger;RM Braziel;DG Maloney;TP Miller;M LeBlanc;RI Fisher
Journal / Conference
Blood 102(11):(#90)
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
S9911

Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia (ALL): a Southwest Oncology Group (SWOG) study (S9400)

Authors
ML Slovak;KJ Kopecky;H Gundacker;F Appelbaum;DH Boldt;V Pullarkat;SJ Forman
Journal / Conference
Blood 102(11):(#2223)
Year
2003
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9400

Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standrad dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup trial S9321

Authors
B Barlogie;R Kyle;K Anderson;P Greipp;H Lazarus;J Jacobson;E Rasmussen;J Cromer;J Crowley
Journal / Conference
Blood 102(11):(#135)
Year
2003
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Loss of MHC class II gene and protein expression in diffuse large B cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival: a follow-up study to the NIH director's challenge leukemia and lymphoma molecular profiling project (LLMPP)

Authors
L Rimsza;R Roberts;T Miller;J Unger;M LeBlanc;R Braziel;D Weisenburger;WC Chan;T Greiner;K Muller-Hermelink;E Jaffe;RD Gascoyne;E Campo;D Fuchs;C Spier;R Fisher;L Staudt;T Grogan
Journal / Conference
Blood 102(11):(#1417)
Year
2003
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Loss of major histocompatibility class II (MHCII) expression in nodal diffuse large B cell lymphoma (DLBCL) is highly coordinated and unlikely related to chromosomal deletions

Authors
L Rimsza;R Roberts;E Campo;T Grogan;S Bea;I Salaverria;A Zettl;R Fisher;J Unger;M LeBlanc;L Staudt;R Gascoyne;W Chan;D Weisenburger;T Greiner;E Jaffe;R Braziel;K Muller-Hermelink;T Miller
Journal / Conference
Blood 102(11):(#3321)
Year
2003
Research Committee(s)
Lymphoma

Gene expression microarray analysis of de novo CD5+ diffuse large B-cell lymphoma (LLMPP study): a distinct entity?

Authors
RD Gascoyne;S Dave;A Zettl;S Bea;WC Chan;A Rosenwald;ES Jaffe;E Campo;J Delabie;D Weisenburger;G Ott;K Muller-Hermelink;L Rimsza;T Grogan;JM Connors;G Wright;LM Staudt
Journal / Conference
Blood 102(11):(#621)
Year
2003
Research Committee(s)
Lymphoma

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky memorial lecture

Authors
JM Unger;M LeBlanc;JJ Crowley;HB Grossman;RB Natale;AJ Wozniak;JR Berenson;AF List;WA Peters III;RC Flanigan;JS Macdonald;M Al-Sarraf;IM Thompson;CA Coltman Jr
Journal / Conference
Journal of Clinical Oncology 21(23s):246s-252s
Year
2003